|
葉酸、維生素B12、瑞舒伐他汀對(duì)冠心病合并高脂血癥患者聯(lián)合治療價(jià)值分析
泰州市人民醫(yī)院 帥曄 2020/1/12 19:23:15
Value of folic acid, vitamin B12 and rosuvastatin in the treatment of patients with coronary heart disease complicated with hyperlipidemia
摘要：目的：研究維生素B12、葉酸和瑞舒伐他汀聯(lián)合治療冠心病合并高脂血癥的臨床療效。方法：選取2017年1月～2019年1月在我院治療的104例患者作為研究對(duì)象，將他們隨機(jī)均分為兩組，即對(duì)照組和觀察組，兩組各52例。對(duì)照組采取口服瑞舒伐他汀鈣治療，觀察組在對(duì)照組的基礎(chǔ)上結(jié)合維生素B12和葉酸聯(lián)合治療，比較兩組患者治療的總有效率和治療后血脂指標(biāo)。結(jié)果：觀察組治療的總有效率為98.08％高于對(duì)照組的86.54％；觀察組患者治療后的血脂指標(biāo)優(yōu)于對(duì)照組，兩組比較差異皆具有統(tǒng)計(jì)學(xué)意義，P＜0.05。結(jié)論：維生素B12、葉酸和瑞舒伐他汀結(jié)合治療高血脂癥合并冠心病療效顯著，值得臨床借鑒。
ABSTRACT: Objective: To study the clinical efficacy of vitamin B12, folic acid and rosuvastatin in the treatment of coronary heart disease with hyperlipidemia. Methods: 104 patients treated in our hospital from January 2017 to January 2019 were randomly divided into two groups: control group and observation group, 52 cases in each group. The control group was treated with oral rosuvastatin calcium, while the observation group was treated with vitamin B12 and folic acid on the basis of the control group. The total effective rate and blood lipid index were compared between the two groups. Results: The total effective rate of the observation group was 98.08% higher than 86.54% of the control group, and the blood lipid index of the observation group was better than that of the control group after treatment, the difference between the two groups was statistically significant (P ﹤ 0.05). Conclusion: The combination of vitamin B12, folic acid and rosuvastatin is effective in the treatment of hyperlipidemia with coronary heart disease, which is worthy of clinical reference.
關(guān)鍵詞：葉酸；維生素B12；瑞舒伐他��；冠心病合并高脂血癥
Key words: folic acid; vitamin B12; rosuvastatin; coronary heart disease with hyperlipidemia
冠心病就是冠狀動(dòng)脈粥樣化的簡(jiǎn)稱，它是一種心血管疾病，屬于慢性疾病，隨著我國(guó)步入老齡化社會(huì)，它的發(fā)病率逐年上升，具相關(guān)研究表明，如果低密度脂蛋白膽固醇（LDL-C）或血清總膽固醇（TC）升高，就會(huì)導(dǎo)致冠心病發(fā)生[1]。因此，有效的降血脂可以改善冠心病癥狀，瑞舒伐他汀作為一種治療冠心病合并高脂血癥的藥物，它可以降低LDL、TG和TC，可以增加HDL，如果單獨(dú)使用，整體療效不佳，因此，本研究就維生素B12、葉酸和瑞舒伐他汀結(jié)合在治療高血脂癥合并冠心病的臨床效果進(jìn)行研究，現(xiàn)報(bào)告如下。
1.臨床資料及方法
1.1一般資料
選取2017年1月～2019年1月在我院治療的104例冠心病合并高脂血癥患者參與（未完，下一頁(yè)）
|